Reference

Study on the usefulness of seratrodast in the treatment of chronic pulmonary emphysema

Study on the usefulness of seratrodast in the treatment of chronic pulmonary emphysema. Horiguchi, Takahiko; Tachikawa, Soichi; Kondo, Rieko; Shiga, Mamoru; Hirose, Masahiro; Fukumoto, Koji (Department of Internal Medicine, Fujita Health University Second Hospital, Nagoya, Japan). Arzneimittel-Forschung, 52(10), 764-768 (English) 2002 Editio Cantor Verlag. CODEN: ARZNAD. ISSN: 0004-4172. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacology) It has been reported that the biosynthesis of thromboxane A2 (TXA2) is enhanced in platelets in the presence of chronic obstructive pulmonary disease (COPD), and 11-dehydro-TXB2, a urinary metabolite of thromboxane, also increases in blood. In the present study, seratrodast (CAS 112665-43-7, Bronica), a TXA2 receptor antagonist, was administered to 14 patients with chronic pulmonary emphysema in the stable phase for 8 wk. Respiratory distress was evaluated in the attending physicians' judgments using the Hugh-Jones (H-J) classification, and also by the patients themselves using the Borg scale. Respiratory function tests, including forced vital capacity (FVC), percent of one second forced expiratory vol. (FEV1.0%), arterial blood gases during respiration of room air, and peak expiratory flows (PEF) (morning and evening), and measurement of plasma 11-denhydro-TXB2 and TXB2 levels were performed before and 8 wk after the start of administration, as well as at the time of the start of administration. The results revealed significant improvement of respiratory distress, evaluated on both the H-J classification and the Borg scale, at week 8. Although no significant changes were obsd. in plasma TXB2 levels, the plasma 11-dehydro-TXB2 level significantly decreased at week 8. Among the respiratory function parameters examd., only FVC was significantly improved. These results indicated that seratrodast is useful for the improvement of respiratory distress in patients with chronic pulmonary emphysema in the stable phase.

Seratrodast (AA-2414) - a novel thromboxane-A2 receptor antagonist

Seratrodast (AA-2414) - a novel thromboxane-A2 receptor antagonist. Samara, Emil E. (Pharmaceutical Product Division, Abbott Laboratories, Abbott Park, IL 60064-3500, USA). Cardiovascular Drug Reviews, 14(3), 272-285 (English) 1996 Neva Press.There are some reagents like 112665-43-7 is used in this study. CODEN: CDREEA. ISSN: 0897-5957. DOCUMENT TYPE: Journal; General Review CA Section: 1 (Pharmacology) A review with 38 refs. of pharmacol. and toxicol. studies of seratrodast. .